Abstracts tagged "Epidemiologic methods and systemic lupus erythematosus (SLE)"

Abstract Number: 2804 • 2018 ACR/ARHP Annual Meeting
Identifying Lupus Patients in Electronic Health Records: Development and Validation of Machine Learning Algorithms and Application of Rule-Based Algorithms
April Jorge¹, Victor M. Castro², April Barnado³, Vivian Gainer², Chuan Hong⁴, Tianxi Cai², Robert Carroll⁵, Leslie Crofford³, Karen Costenbader⁶, Katherine P. Liao⁷, Elizabeth Karlson⁶ and Candace H. Feldman⁶, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Research Information Systems and Computing, Partners Healthcare, Boston, MA, ³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁴Harvard T.H. Chan School of Public Health, Boston, MA, ⁵Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: To utilize electronic health records (EHR) to study SLE, phenotypic algorithms are needed to accurately identify these patients. We aimed to generate an EHR…
Abstract Number: 149 • 2015 ACR/ARHP Annual Meeting
Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus (SLE) Initiating Treatment with Belimumab in a US Commercially Insured Database: 2010-2014
Deanna Hill¹, Hong Kan², Peter Egger³, David J. Chang⁴, Amanda Eudy^1,5, Joe Maskell³ and Karen H. Costenbader⁶, ¹Worldwide Epidemiology, GlaxoSmithKline, Collegeville, PA, ²Value Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC, ³Worldwide Epidemiology, GlaxoSmithKline, Stockley Park, United Kingdom, ⁴US Medical Affairs, GlaxoSmithKline, Philadelphia, PA, ⁵Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Belimumab, a B-lymphocyte stimulator, was FDA-approved March 2011 for the treatment of adult patients with active, autoantibody-positive SLE receiving standard of care (SOC) medications.…
Abstract Number: 990 • 2015 ACR/ARHP Annual Meeting
Performance of the Systemic Lupus International Collaborating Clinic Classification Criteria Versus the 1982 and Revised 1997 American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus: A Population-Based Study
Patompong Ungprasert¹, Cynthia S. Crowson² and Vaidehi Chowdhary¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous presentations. Therefore, classification criteria are required to help improve diagnostic accuracy in clinical practice…
Abstract Number: 3158 • 2015 ACR/ARHP Annual Meeting
Impact of Family History of Systemic Lupus Erythematosus on Risk of Autoimmune Diseases: National Cohort Study in Denmark 1977-2012
Constance Jensina Ulff-Møller¹, Jacob Simonsen², Søren Jacobsen¹ and Morten Frisch², ¹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ²Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease (AID), which develops through the interplay of genetic, epigenetic and environmental factors and may cluster…
Abstract Number: 2510 • 2013 ACR/ARHP Annual Meeting
The Epidemiology Of Systemic LUPUS Erythematosus and Clinical Features Of Patients At A Single Center In Northwestern Turkey
Omer Nuri Pamuk¹, Salim Dönmez², Gokce Busra Calayir³ and Cigdem Mengus⁴, ¹Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey, ²Rheumatology, Yüzüncü Yıl University Medical Faculty, Edirne, Turkey, ³Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ⁴Internal Medicine, Trakya University Medical Faculty, Edirne, Turkey
Background/Purpose: We evaluated the clinical features, treatment modalities, treatment responses and prognosis of patients diagnosed with systemic lupus erythematosus (SLE). We also estimated the prevalence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].